Form 4: MaxCyte Director John Johnston Executes Option, Sells Shares Under 10b5-1 Plan

Director John Johnston exercised stock options and sold shares of MaxCyte, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 26, 2024, John Johnston, a director of MaxCyte, Inc., exercised stock options to acquire 5,000 shares of common stock at a price of $2.142 per share.
• Simultaneously, Johnston sold 5,000 shares of MaxCyte common stock at a weighted average price of $4.405 per share, with individual sales prices ranging from $4.37 to $4.43.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on March 28, 2023.
• Following these transactions, Johnston directly owns 120,583 shares of MaxCyte common stock and holds options to purchase 617 shares.
• The stock options vest monthly over a period of forty-eight months, commencing on April 4, 2019.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of insider trading activity under a pre-arranged plan. There's no indication of positive or negative sentiment towards the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives and directors to utilize 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The filing itself doesn't provide specific insight into MaxCyte's overall performance or competitive landscape.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the director selling shares, but the existence of a 10b5-1 plan mitigates concerns about insider information being used.

Key Dates